articles by Himani Chandna


Usage of masks should be relaxed among children say experts as skin infection risk increased

Also, as the benefit of using masks is low when the virus circulation is limited, experts feel the central government should remove the compulsion for kids.


Why manufacturing licence of Remdesivir was not given to pharmaceutical PSUs, asks Parliamentary panel

Since Remdesivir has been included in the National Treatment Protocol as an optional drug in curing critical coronavirus patients, the committee recommended that the Centre conduct scientific studies to check the efficacy of the drug and asked it to explore possibilities to manufacture COVID essential drugs by PSUs under it


No gifts or vacation offers: Govt unveils draft code to stop bribing of doctors by medical device firms

While the pharmaceutical sector has its own set of codes, different ones have been drafted for the medical devices sector as the government moves to regulate the latter as a separate industry going forward


Punjab Assembly election results: Ecstatic party workers dance to 'Ik Mauka Dena Appa Kejriwal Nu, Ik Mauka Dena Bhagwant Mann Nu’

AAP has surpassed 89 seats of the 117 seats and political heavyweights, including Amarinder Singh and Navjot Sidhu, are trailing in their constituencies to AAP candidates


Indians purchased 1.2-cr 'controversial' anti-COVID Molnupiravir pills in first month of launch

On 5 January, in a weekly press briefing, ICMR director-general Dr Balram Bhargava said that the drug has major safety concerns and it can cause teratogenicity and mutagenicity


Union Budget 2022: Why Centre has reduced COVID-19 vaccine budget to Rs 5,000 crore

Experts are of the opinion that the reduction in allocation of funds hints that the Centre has done its job of providing free vaccines across the country and people may have to shell out for booster shots


Centre may slash rates of popular but costly drugs, reviews essential medicines list

The health ministry has involved the Bureau of Pharma PSUs of India (BPPI) – the department running central govt's pharmacy outlets called Jan Aushadhi Kendra – to send the data on sales of selected molecules


Biological E's Corbevax booster trial to begin soon: 360 participants, 8 centres, 2 groups

The study will capture data – under the primary endpoints – virus neutralising antibodies against SARS-CoV-2 at baseline and again at 28 days post booster dose.


New COVID-19 treatment rules: India cuts down use of Remdesivir, Tocilizumab, multivitamins, steroids

According to the new guidelines, Remdesivir may be considered only in patients who have completed 10 days since the start of the symptoms and require supplemental oxygen.


Central govt to study drug pricing in 10 countries to make medicines affordable in India

The objective of the research is to understand the drug pricing methodology adopted in the international market covering at least 10 countries, including China, Sri Lanka, Bangladesh and the United States


COVID-19 treatment: Centre plans to create live dashboard to monitor availability of key drugs

The move is driven by the learnings from the second wave when COVID-19 critical medicines were hoarded and blackmarketed causing shortages in the market


Gap in our understanding of the science behind COVID-19 booster dose, says vaccine panel chief

We must understand that our understanding of Omicron is still evolving and it will take another two to three weeks to derive any concrete understanding, Dr NK Arora said


In the time of Omicron, immunity war and the Endgame: What we may or may not avenge in 2022

Experts say there will be an obvious race between vaccines and variants in the coming years till the Covid-19 pandemic becomes endemic. But much depends on individual behaviour.


Will India get booster doses soon? Narendra Modi government launches study as Omicron cases surge

The advent of Omicron, a new mutation of the coronavirus, has sparked calls for booster doses in the country


No need for boosters, two jabs of vaccine enough to fight COVID, says NTAGI member

Dr Jayaprakash Muliyil said NTAGI members have been deliberating over the issue of launching booster doses in India and another meeting is slated to happen next week


India likely to witness Omicron peak by February-end; to be less severe than second wave, says COVID-19 supermodel panel

Members of the panel also added that the Omicron-driven spike in COVID-19 cases in UK is irrelevant to India as the former has low sero-positivity and uses mostly mRNA vaccines that seem to offer protection only for a short duration


Early phase of variant always mild, understanding on Omicron possible by December-end, says top Indian scientist

The denominator is larger when it comes to India due to its size of population and hence, the total number of severe cases will be large enough to break the entire healthcare system, said Dr Anurag Agrawal, director, Institute of Genomics and Integrative Biology


Omicron variant likely to be present in all major Indian cities, not coming from airports, says top Indian scientist

Dr Rakesh Mishra, the chief of Centre for Cellular and Molecular Biology, said that vaccinations, wearing face masks, maintaining social distance and hand hygiene are of utmost importance in the fight against the disease


Online sale of medicines: Centre to introduce new law; all you need to know

Online sales of medicines, also known as e-pharmacies, are currently not regulated and their existence is constantly met with opposition from brick and mortar chemists


From faster reimbursements to incentives for model hospitals, Ayushman Bharat all set to reboot

The government’s flagship health scheme provides an annual health cover of Rs 5 lakh per family to 10 crore poor and vulnerable families for secondary and tertiary care hospitalisation